Eli Lilly stock soars while Novo Nordisk sinks—why the weight-loss leaders are headed in opposite directions

Key Takeaways Eli Lilly's stock surged Wednesday while shares of weight-loss rival Novo Nordisk slumped, widening the gap ...

Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar

Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...

Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?

Meanwhile, Novo Nordisk's (NYSE: NVO) obesity franchise made the Denmark-based drugmaker 82.3 billion Danish krone (roughly ...

Eli Lilly rebounds on Q4 beat after Novo-led decline

Eli Lilly (LLY) stock rises after Q4 2025 earnings beat and strong 2026 outlook following a drop led by an underwhelming ...

Eli Lilly stock surges after company touts strong sales outlook as rival Novo Nordisk continues plunge

The rally in Lilly also pressured shares of its main weight-loss rival, Danish drugmaker Novo Nordisk ( NVO ), for a second ...

Lilly sees surging sales in contrast to obesity rival Novo

Eli Lilly & Co. provided an upbeat sales forecast for the year Wednesday as strong demand for its weight loss drug cemented ...
BioSpace

Novo’s Wegovy Pill Success Is ‘Good News’ for Orforglipron, Lilly Execs Say

Novo Nordisk and Eli Lilly both think the Wegovy pill is doing well, but the American rival sees the successful launch as a harbinger of good news for its own candidate, orforglipron, which is ...